Latest Volitionrx Ltd (VNRX) Headlines
CalNaturale Svelte® Shares Tips For Discovering A Healthier You In 2014
PR Newswire - Thu Jan 09, 2:54PM CST
To ring in the New Year and help make health and fitness resolutions stick through the winter and beyond, CalNaturale Svelte®, the premium line of USDA Certified organic protein shakes that provides great taste, sustained nutrition and energy through pure and simple ingredients, is offering simple ways for people to stay "Svelte" this season. Known for its positive, on-package affirmations like "Hello Beautiful(TM)" and "Looking Good(TM)," the company aims to help individuals looking to achieve new health goals in 2014 and look and feel their best.
CEGA Welcomes Jimmy Delshad to Board of Directors
PR Newswire - Wed Dec 18, 6:00AM CST
Concurrent with the launch of the CEGA Solar Fund LP, CEGAlliance Inc. is pleased to welcome the Honorable Jimmy Delshad, former Mayor of Beverly Hills, California, as its Vice Chairman of its Board of Directors. This well-timed addition brings high potential to the CEGA Solar Fund LP, through Delshad's prestigious reputation.
VolitionRx Finds Simple Blood Test Detects 85% of Colorectal Cancers and Over 50% of Polyps
PR Newswire - Mon Dec 02, 5:30AM CST
VolitionRx Limited (VNRX:OB), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today releases new data showing that when combining two of its proprietary NuQ® assays into one test, they can achieve 85% detection rates at 85% specificity for colorectal cancer. The data also shows that Volition's two-assay test can detect more than 50% of precancerous polyps. These new findings come from its ongoing prospective study with CHU Dinant Godinne | UCL Namur Hospital in Belgium.
VolitionRx to Present at the 6th Annual LD Micro Conference
PR Newswire - Fri Nov 29, 7:30AM CST
VolitionRx Limited (VNRX:OB), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today announces it will be presenting at the Sixth Annual LD Micro Conference.
VolitionRx Expands Sample Size to 11,000 in Pivotal Colorectal Cancer Trial with Hvidovre Hospital, Denmark
PR Newswire Europe - Thu Nov 14, 5:30AM CST
VolitionRx Limited [http://www.volitionrx.com/] , a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today announced an increase of 55% (from 6,000 to 11,000) in the number of prospective blood samples to be included in its forthcoming colorectal cancer clinical trial at no additional cost beyond the $1.85 million already announced. The randomised, blinded study is designed to evaluate the validity of VolitionRx's proprietary NuQ(R) panel as a first-step screening tool for colorectal cancer.
First VolitionRx Study Data Presented at CNAPS, Baltimore
PR Newswire - Thu Nov 07, 5:30AM CST
VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today announces the publication of preliminary data from an ongoing independent trial of one of its NuQ® assays. Priv.-Doz. Dr. Stefan Holdenrieder will present a poster at the eighth CNAPS (Circulating Nucleic Acids in Plasma and Serum) congress in Baltimore, MD, USA, showing results from his third party study into the effectiveness of a single NuQ assay for detecting patients with colorectal cancers.
VolitionRx-led Consortium Awarded euro 780 000 ($1M approx.) Eurostars Grant
PR Newswire - Tue Sep 03, 5:30AM CDT
VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, is lead partner of a consortium in a project valued at EUR 779,493 (approx. US$1M) under the EUREKA Eurostars scheme. The project aims to develop new applications of the Nucleosomics biomarker technology in inflammatory disease. The research will build on VolitionRx's ongoing cancer diagnostic research program.
VolitionRx to use Innova Biosciences' Biotin Technology in its Epigenetic Research Kits
PR Newswire - Mon Jul 22, 5:30AM CDT
VolitionRx Limited (OTC: VNRX), a life sciences company focused on the development of blood-based diagnostic tests, has signed a non-exclusive in-licensing agreement with Innova Biosciences, a specialist provider of bioconjugation systems, based in Cambridge, UK. Under the agreement, Innova Biosciences will supply its Lightning-Link® Biotin technology for Volition's NuQ® epigenetic profiling research kits. The addition of the Lightning-Link technology will help Volition to improve the accuracy of its test, whilst speeding up production of the research kits.
VolitionRx Embarks on Colorectal Cancer Trial with Hvidovre Hospital, Denmark
PR Newswire - Wed May 29, 5:30AM CDT
VolitionRx Limited (VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, announces that it has signed an agreement with Hvidovre Hospital, University of Copenhagen, Denmark, for two colorectal cancer (CRC) clinical trials. The trials will analyze blood samples from approximately 10,800 patients, using VolitionRx's proprietary NuQ® tests.
Racepoint Group Appointed by VolitionRx to Raise Awareness of its new Early-Stage Cancer Diagnostic
PR Newswire - Wed May 01, 5:30AM CDT
VolitionRx Limited (OTC: VNRX), a life sciences company that is developing blood-based diagnostic tests for different types of cancer, has retained Racepoint Group as its public relations agency of record. The company's tests are based on the science of Nucleosomics® which is the practice of identifying and measuring nucleosomes in the bloodstream - an indication that cancer is present.
VolitionRx Files Two Patent Applications
PR Newswire - Thu Apr 04, 5:30AM CDT
VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests, announces that it has filed two new patent applications. The first patent application is an extension to the Nucleosomics® technology for the detection of histone modifications in nucleosomes; the second covers the use of Volition's Nucleosomics® technology in personalized medicine as a predictor of the efficacy of cancer treatment.
VolitionRx Hires Head of US Operations, Jason Terrell MD
PR Newswire - Tue Mar 26, 6:00AM CDT
VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests, announces that it has hired Jason Terrell MD as Head of US Operations. Dr Terrell will initially be responsible for facilitating Volition's entry into the US market, acting as the company's FDA liaison and pursuing and negotiating FDA compliant US clinical trials.
CalNaturale Svelte® Shares Tips For Discovering A Healthier You In 2014
PR Newswire - Thu Jan 09, 2:54PM CST
To ring in the New Year and help make health and fitness resolutions stick through the winter and beyond, CalNaturale Svelte®, the premium line of USDA Certified organic protein shakes that provides great taste, sustained nutrition and energy through pure and simple ingredients, is offering simple ways for people to stay "Svelte" this season. Known for its positive, on-package affirmations like "Hello Beautiful(TM)" and "Looking Good(TM)," the company aims to help individuals looking to achieve new health goals in 2014 and look and feel their best.
CEGA Welcomes Jimmy Delshad to Board of Directors
PR Newswire - Wed Dec 18, 6:00AM CST
Concurrent with the launch of the CEGA Solar Fund LP, CEGAlliance Inc. is pleased to welcome the Honorable Jimmy Delshad, former Mayor of Beverly Hills, California, as its Vice Chairman of its Board of Directors. This well-timed addition brings high potential to the CEGA Solar Fund LP, through Delshad's prestigious reputation.
VolitionRx Finds Simple Blood Test Detects 85% of Colorectal Cancers and Over 50% of Polyps
PR Newswire - Mon Dec 02, 5:30AM CST
VolitionRx Limited (VNRX:OB), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today releases new data showing that when combining two of its proprietary NuQ® assays into one test, they can achieve 85% detection rates at 85% specificity for colorectal cancer. The data also shows that Volition's two-assay test can detect more than 50% of precancerous polyps. These new findings come from its ongoing prospective study with CHU Dinant Godinne | UCL Namur Hospital in Belgium.
VolitionRx to Present at the 6th Annual LD Micro Conference
PR Newswire - Fri Nov 29, 7:30AM CST
VolitionRx Limited (VNRX:OB), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today announces it will be presenting at the Sixth Annual LD Micro Conference.
VolitionRx Expands Sample Size to 11,000 in Pivotal Colorectal Cancer Trial with Hvidovre Hospital, Denmark
PR Newswire Europe - Thu Nov 14, 5:30AM CST
VolitionRx Limited [http://www.volitionrx.com/] , a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today announced an increase of 55% (from 6,000 to 11,000) in the number of prospective blood samples to be included in its forthcoming colorectal cancer clinical trial at no additional cost beyond the $1.85 million already announced. The randomised, blinded study is designed to evaluate the validity of VolitionRx's proprietary NuQ(R) panel as a first-step screening tool for colorectal cancer.
First VolitionRx Study Data Presented at CNAPS, Baltimore
PR Newswire - Thu Nov 07, 5:30AM CST
VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today announces the publication of preliminary data from an ongoing independent trial of one of its NuQ® assays. Priv.-Doz. Dr. Stefan Holdenrieder will present a poster at the eighth CNAPS (Circulating Nucleic Acids in Plasma and Serum) congress in Baltimore, MD, USA, showing results from his third party study into the effectiveness of a single NuQ assay for detecting patients with colorectal cancers.
VolitionRx-led Consortium Awarded euro 780 000 ($1M approx.) Eurostars Grant
PR Newswire - Tue Sep 03, 5:30AM CDT
VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, is lead partner of a consortium in a project valued at EUR 779,493 (approx. US$1M) under the EUREKA Eurostars scheme. The project aims to develop new applications of the Nucleosomics biomarker technology in inflammatory disease. The research will build on VolitionRx's ongoing cancer diagnostic research program.
VolitionRx to use Innova Biosciences' Biotin Technology in its Epigenetic Research Kits
PR Newswire - Mon Jul 22, 5:30AM CDT
VolitionRx Limited (OTC: VNRX), a life sciences company focused on the development of blood-based diagnostic tests, has signed a non-exclusive in-licensing agreement with Innova Biosciences, a specialist provider of bioconjugation systems, based in Cambridge, UK. Under the agreement, Innova Biosciences will supply its Lightning-Link® Biotin technology for Volition's NuQ® epigenetic profiling research kits. The addition of the Lightning-Link technology will help Volition to improve the accuracy of its test, whilst speeding up production of the research kits.
VolitionRx Embarks on Colorectal Cancer Trial with Hvidovre Hospital, Denmark
PR Newswire - Wed May 29, 5:30AM CDT
VolitionRx Limited (VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, announces that it has signed an agreement with Hvidovre Hospital, University of Copenhagen, Denmark, for two colorectal cancer (CRC) clinical trials. The trials will analyze blood samples from approximately 10,800 patients, using VolitionRx's proprietary NuQ® tests.
Racepoint Group Appointed by VolitionRx to Raise Awareness of its new Early-Stage Cancer Diagnostic
PR Newswire - Wed May 01, 5:30AM CDT
VolitionRx Limited (OTC: VNRX), a life sciences company that is developing blood-based diagnostic tests for different types of cancer, has retained Racepoint Group as its public relations agency of record. The company's tests are based on the science of Nucleosomics® which is the practice of identifying and measuring nucleosomes in the bloodstream - an indication that cancer is present.
VolitionRx Files Two Patent Applications
PR Newswire - Thu Apr 04, 5:30AM CDT
VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests, announces that it has filed two new patent applications. The first patent application is an extension to the Nucleosomics® technology for the detection of histone modifications in nucleosomes; the second covers the use of Volition's Nucleosomics® technology in personalized medicine as a predictor of the efficacy of cancer treatment.
VolitionRx Hires Head of US Operations, Jason Terrell MD
PR Newswire - Tue Mar 26, 6:00AM CDT
VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests, announces that it has hired Jason Terrell MD as Head of US Operations. Dr Terrell will initially be responsible for facilitating Volition's entry into the US market, acting as the company's FDA liaison and pursuing and negotiating FDA compliant US clinical trials.
